418th

New to The Street Airs Episode #418, Five Corporate Interviews, Broadcasting on the Fox Business Network, Tonight, Monday, December 19, 2022, at 10:30 PM PT

Retrieved on: 
Lundi, décembre 19, 2022
Ecology, Telehealth, FMW, Sensation, Smell, Growth, DVLP, Soil, Big Tech, JV, OTCQX, Privacy, CSE, Nutrient, Atmosphere, Health, Interview, 2020 Indian agriculture acts, High Sierra, FRA, Water, Superior, Acquisition, 2009 United Nations Climate Change Conference, Secondary research, Street, Patent, VRM, Television presenter, Cannabis, Garden, Third party, Smokeless tobacco, Social media, Hemp, Smoking, FRC, CCW, Tobacco industry, Patient, CBD, Relaxation, 418th, Internet, Conference, SHOT, Marketing, Television, Tobacco, Abbie Hoffman: American Rebel, Kellie

Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.

Key Points: 
  • Email/Messenger Privacy Solutions - Sekur Private Data, Ltd.'s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Alain Ghiai, CEO.
  • Tonight, New to The Street airs TV Host Jane King's Nasdaq MarketSite studio interview with VRM BioLogik Group’s Founder, Ken Bellamy, and CEO, Kellie Walters.
  • From the air, one can see the improved soil composition compared to the surrounding desert, capable of growing crops.
  • As featured guests and keynote speakers, VRM explains the business collaboration and relationship between VRM and SGTM .

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Retrieved on: 
Mardi, février 22, 2022
GLOBE, Cholangiocarcinoma, Population, 418th, Biliary tract, Security (finance), NASDAQ, Protide, Company, 644th Bomb Squadron, NCNA, Private Securities Litigation Reform Act, Cisplatin, U.S. Securities and Exchange Commission, Gallbladder, Cancer, Nominal interest rate, Terminology, Endpoint security, Liver, FDA, Forward-looking statement, Bile, Patient, Survival, NDA, Goal, SEC, Pharmaceutical industry, Medical imaging, ORR

EDINBURGH, United Kingdom, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has completed enrollment of the number of patients in the ongoing Phase III NuTide:121 study required to conduct the second interim analysis, which is expected to occur in the second half of 2022 after the 644th patient has completed 28 weeks of follow-up. The NuTide:121 study is comparing Acelarin combined with cisplatin to the global standard of care, gemcitabine plus cisplatin, as a first-line treatment for patients with advanced biliary tract cancer. As previously announced, NuCana expects to conduct the first interim analysis after the 418th patient has completed 28 weeks of follow-up, which is expected to occur in the first half of 2022.

Key Points: 
  • Due to the larger number of patients included in the second interim analysis, an improvement in ORR of approximately 9% or more would be statistically significant.
  • Mr. Griffith continued: In the ABC-08 study of first-line patients with biliary tract cancer, Acelarin plus cisplatin achieved an ORR of 44% among the evaluable population.
  • Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, are a group of cancers originating in the biliary tract.
  • Acelarin is in a Phase 3 study for patients with advanced biliary tract cancer.

NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study

Retrieved on: 
Mercredi, septembre 15, 2021
U.S. Securities and Exchange Commission, Cancer, Security (finance), NCNA, Liver, NDA, Protide, Patient, FDA, Forward-looking statement, Biliary tract, 418th, Cholangiocarcinoma, Company, Private Securities Litigation Reform Act, Terminology, Survival, ORR, NASDAQ, Bile, Gallbladder, Endpoint security, GLOBE, Cisplatin, Population, Nominal interest rate, Goal, SEC, Medical imaging

EDINBURGH, United Kingdom, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has completed enrollment of the number of patients in the ongoing Phase III NuTide:121 study required to conduct the first interim analysis. The study, which is comparing Acelarin combined with cisplatin to the global standard of care, gemcitabine plus cisplatin, as a first-line treatment for patients with advanced biliary tract cancer, has enrolled 418 patients with measurable disease. The first interim analysis will be conducted after the 418th patient has completed 28 weeks of follow-up, which is expected to occur in the first half of 2022. NuCana believes that a statistically significant improvement in the Objective Response Rate (ORR) at the first interim analysis, accompanied by positive trends in other endpoints, has the potential to allow for accelerated approval of a new drug application (NDA) for Acelarin in the United States. Recruitment in the NuTide:121 study, which is intended to enroll up to 828 patients, is ongoing and NuCana believes subsequent analyses could provide the confirmatory data to support full (regular) approval.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has completed enrollment of the number of patients in the ongoing Phase III NuTide:121 study required to conduct the first interim analysis.
  • Biliary tract cancer is a devastating disease and there is a significant need for more effective medicines.
  • Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, are a group of cancers originating in the biliary tract.
  • Acelarin is in a Phase 3 study for patients with advanced biliary tract cancer.